[ij] [ij] [ij] 
Email id

Research Journal of Pharmacy and Technology
Year : 2017, Volume : 10, Issue : 8
First page : ( 2527) Last page : ( 2534)
Print ISSN : 0974-3618. Online ISSN : 0974-360X.
Article DOI : 10.5958/0974-360X.2017.00447.4

Design, Synthesis and In Silico Molecular Docking Study of N-carbamoyl-6-oxo-1-phenyl-1, 6-dihydropyridine-3-carboxamide derivatives as Fibroblast growth factor 1 inhibitor

Misra Prem Shankar1, Ravichandiran V.2, Aanandhi M. Vijey3,*

1Research Scholar, Department of Pharmaceutical Chemistry and Analysis, Vels University, (VISTAS), Chennai-600117, Tamilnadu, India

2NIPER, Kolkata, India

3Department of Pharmaceutical Chemistry and Analysis, Vels University (VISTAS), Chennai-600117. Tamilnadu, India

*Corresponding Author E-mail: hodpchemistry@velsuniv.ac.in

Online published on 26 March, 2018.


A novel series of N-carbamoyl-6-oxo-1-phenyl-1, 6-dihydropyridine-3-carboxamide derivatives (A1-A6) were synthesized by various substitution and their structures were confirmed by spectral and elemental analyses. The cytotoxic activity of the newly synthesized compounds was docked against fibroblast growth factor 1 (FGF1). These FGFR cascades play crucial roles in tumor cell proliferation, angiogenesis, migration, and survival. FGFRs were also identified in a variety of human cancers such as ovarian cancer, myeloproliferative syndromes, lymphomas, prostate and breast cancers as well as other malignant diseases. The molecular docking study was used for confirming their interaction with fibroblast growth factor 1. Thorough in silico molecular docking study, the result showed that all synthesized derivatives (A1-A6) have low binding energy (Table 1) and have good affinity toward their active pocket. Thus the synthesized derivatives considered as good anti cancer agents.



2-pyridone derivatives, Fibroblast growth factor 1, Molecular docking methodology.


║ Site map ║ Privacy Policy ║ Copyright ║ Terms & Conditions ║ Page Rank Tool
755,504,793 visitor(s) since 30th May, 2005.
All rights reserved. Site designed and maintained by DIVA ENTERPRISES PVT. LTD..
Note: Please use Internet Explorer (6.0 or above). Some functionalities may not work in other browsers.